化生性乳腺癌（MBC）是一种罕见且异质性的乳腺癌亚型，我们对其长期结果的理解存在重大差距。这项回顾性队列研究旨在通过仔细检查 MBC 的病理和临床方面来弥补这些差距，以加强临床决策并完善患者护理策略。这项基于登记的回顾性队列研究包括年龄≥21 岁的被诊断患有 MBC 或基质产生的女性癌。数据来自2001年1月至2020年8月从XXXX的XXXX登记处获得，其中包括23,935名患者。分析了人口统计学和临床​​病理学特征、新辅助化疗反应和生存结果。统计评估涉及单变量和多变量 Cox 比例风险模型以及 Kaplan-Meier 生存分析。本研究纳入了 170 名患者； 87.1% 患有非转移性疾病，12.9% 患有转移性疾病。患者诊断时的年龄范围为 46 岁至 65 岁（中位年龄 56 岁）。该队列的主要特征是临床分期晚期 (77.6%)、淋巴结阴性 (67.6%) 和 3 级疾病 (74.1%)。在接受治愈性治疗的患者中，新辅助化疗的病理完全缓解率为 19.2%，疾病进展率为 46.2%。多变量分析显示，辅助放射治疗显着改善了总生存期 (OS) 和无病生存期 (DFS)，风险比 (HR) 为 0.29（95% 置信区间 [CI]，0.13 - 0.62；p < 0.005）和 0.23 （95% CI，0.10-0.50；p < 0.005）。临床 T3 和 T4 分期以及淋巴结受累与不良预后相关。新辅助化疗后疾病稳定与较差的 OS 和 DFS 相关。这项研究揭示了 MBC 的复杂情况，并强调了辅助放疗在改善患者预后方面的关键作用。尽管取得了进步，挑战仍然存在，需要继续研究以完善新辅助化疗策略并深入研究影响治疗反应的细微差别因素。版权所有 © 2024。由 Elsevier Inc. 出版。

Metaplastic breast cancer (MBC) is a rare and heterogeneous breast cancer subtype, and there are critical gaps in our understanding of its long-term outcomes. This retrospective cohort study aimed to address these gaps by scrutinizing the pathological and clinical aspects of MBC to enhance clinical decision-making and refine patient care strategies.This registry-based retrospective cohort study included females aged ≥21 years diagnosed with MBC or matrix-producing carcinoma. The data were obtained from January 2001-August 2020 from the XXXX Registry of XXXX, which included 23,935 patients. Demographic and clinicopathological characteristics, neoadjuvant chemotherapy responses, and survival outcomes were analyzed. Statistical assessments involved univariate and multivariate Cox proportional hazards models and Kaplan-Meier survival analyses.This study enrolled 170 patients; 87.1% had non-metastatic disease and 12.9% had metastatic disease. The age of patients at diagnosis ranged from 46 to 65 years (median, 56 years). The cohort's predominant characteristics were advanced clinical stage (77.6%), node negativity (67.6%), and grade 3 disease (74.1%). In patients receiving curative intent treatment, neoadjuvant chemotherapy yielded a pathological complete response of 19.2% and a disease progression rate of 46.2%. Multivariate analysis showed that adjuvant radiation therapy significantly improved overall survival (OS) and disease-free survival (DFS), with hazard ratios (HRs) of 0.29 (95% confidence interval [CI], 0.13 - 0.62; p < 0.005) and 0.23 (95% CI, 0.10-0.50; p < 0.005), respectively. Clinical T3 and T4 stages, and nodal involvement were associated with poor outcomes. Stable disease after neoadjuvant chemotherapy was associated with poor OS and DFS.This study sheds light on the complex landscape of MBC and emphasizes the pivotal role of adjuvant radiotherapy in enhancing patient outcomes. Despite advancements, challenges persist that warrant continued research to refine neoadjuvant chemotherapy strategies and delve into the nuanced factors that influence treatment responses.Copyright © 2024. Published by Elsevier Inc.